21159 ⎘
Medicinal preparations containing antigens or antibodies comprising antibodies
BISPECIFIC ANTIBODIES AND METHODS OF USE
#1202ANTIGEN BINDING PROTEIN TARGETING CD40, AND PREPARATION THEREFOR AND USE THEREOF
#1203ANTIBODIES THAT SPECIFICALLY BIND TO API5 PROTEIN
#1204DEVELOPMENT AND USE OF NOVEL IMMUNOMODULATOR
#1205PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF
#1206Anti-GAL3 Antibodies and Compositions
#1207ANTIGEN-BINDING PROTEIN TARGETING PD-L1 AND CD40, PREPARATION THEREFOR, AND USE THEREOF
#1208COMBINATION THERAPY FOR THE TREATMENT OF CANCER
#1209COMBINATION THERAPY OF KRAS INHIBITOR AND TREG DEPLETING AGENT
#1210ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF
#1211ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO GPRC5D AND CD3 AND MEDICAL USE THEREOF
#1212ANTI-CD19 AGENT AND B CELL TARGETING AGENT COMBINATION THERAPY FOR TREATING B CELL MALIGNANCIES
#1213TREM2 STABILIZING ANTIBODIES
#1214ANTIBODIES SPECIFICALLY BINDING PD-1, TIM-3 OR PD-1 AND TIM-3 AND THEIR USES
#1215MONOVALENT ANTI-TREM2 BINDING MOLECULES AND METHODS OF USE THEREOF
#1216Use of Car and Bite Technology Coupled with an SCFV from an Antibody Against Human Thymidine Kinase 1 to Specifically Target Tumors
#1217ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOF
#1218Novel Mcl-1 inhibitor and combination of Mcl-1 and a BH3 mimetic, such as a Bcl-2 inhibitor
#1219ANTI-CTHRC1 FUSION PROTEINS AND METHODS OF USING THE SAME
#1220TREATMENT OF CLUSTER HEADACHE USING ANTI-CGRP ANTIBODIES
#1221NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE
#1222BISPECIFIC T CELL ENGAGER AND USES THEREOF
#1223PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF
#1224ANTI-SEZ6 ANTIBODY DRUG CONJUGATES AND METHODS OF USE
#1225ANTI-COLLAGEN TRIPLE HELIX REPEAT CONTAINING 1 (CTHRC1) ANTIBODIES AND METHODS OF USING THE SAME
#1226Modulation of Interleukin 17F for Treatment of Infection and Organ Dysfunction
#1227NOVEL APPROACH FOR TREATMENT OF CANCER USING IMMUNOMODULATION
#1228Engineered Probiotic Delivery System for Anti-SARS-COV-2 Treatment and Immunity Against Viruses
#1229ONCOLOGY TREATMENTS USING ZINC AGENTS
#1230METHODS FOR TREATING LYMPHOMA
#1231DE-N-ACETYLATED POLYSIALIC ACID (dPSA) BINDING AGENT AND METHOD OF USING SAME
#1232METHODS, COMPOSITIONS AND USES FOR SEMA7A MONOCLONAL ANTIBODIES
#1233ANTI-CD36 ANTIBODIES AND USES THEREOF
#1234ANTI-CD36 ANTIBODIES AND THEIR USE TO TREAT CANCER
#1235CEACAM5-DEPENDENT 4-1BB-AGONISTIC BISPECIFIC ANTIBODIES
#1236Anti-CD40 Antibodies for Use in Treatment of Sjogren's Syndrome
#1237Anti-NGF Antibodies and Methods Thereof
#1238Anti-NGF Antibodies and Methods Thereof
#1239HIGH AFFINITY ANTIBODIES TO HUMAN IL-6 RECEPTOR
#1240METHOD FOR IN VIVO GENERATION OF MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
#1241ILT3 AND CD3 BINDING AGENTS AND METHODS OF USE THEREOF
#1242RECOMBINANT ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USES THEREOF IN TREATING CANCERS
#1243TREATMENT OF STAPHYLOCOCCUS RELATED DISEASES
#1244ANTI-ETEC ADHESIN PROTEIN ANTIBODIES AND METHODS OF USE
#1245Antibodies Against Henipaviruses
#1246CD80 PROTEIN VARIANT AND CD80 FUSION PROTEIN
#1247Antibody Compositions and Methods of Use Thereof
#1248COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BTK INHIBITOR
#1249METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS
#1250Methods and Compositions Comprising V beta 17 Bispecific T Cell Engagers and Bioengineered Virus Specific Lymphocytes
#1251METHODS OF IMPROVING CANCER IMMUNOTHERAPY
#1252DEPLETING TUMOR-SPECIFIC TREGS
#1253METHODS AND COMPOSITIONS FOR THERAPEUTIC PROTEIN DELIVERY
#1254HUMANIZED CHIMERIC BOVINE ANTIBODIES AND METHODS OF USE
#1255ANTI-CERAMIDE ANTIBODIES
#1256METHODS OF TREATMENT WITH ANTI-FACTOR XI/XIA ANTIBODIES
#1257HIGHLY CONCENTRATED PHARMACEUTICAL FORMULATIONS
#1258ANTI-CD20 ANTIBODIES AND THERAPEUTIC USES THEREOF
#1259HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR
#1260STABILIZED FORMULATIONS CONTAINING ANTI-INTERLEUKIN-6 RECEPTOR (IL-6R) ANTIBODIES
#1261OSMR-SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
#1262METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
#1263METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
#1264Anti-FLT3 Antigen Binding Proteins
#1265CD161 BINDING PROTEINS AND RELATED METHODS
#1266ANTI-CD94 ANTIBODIES AND METHODS OF USE THEREOF
#1267ANTI-CD94 ANTIBODIES AND METHODS OF USE THEREOF
#1268MULTISPECIFIC BINDING AGENTS AND USES THEREOF
#1269RECOMBINANT ANTIBODY, IMMUNOCONJUGATE COMPRISING THE SAME, AND USES THEREOF IN TREATING CANCERS
#1270BISPECIFIC ANTIBODY FUSION MOLECULES AND METHODS OF USE THEREOF
#1271ANTI-LAG-3 ANTIBODIES TO TREAT HEMATOLOGICAL MALIGNANCIES
#1272METHODS OF TREATING CANCER WITH ANTIBODIES AGAINST TIM3
#1273LAG-3 AGONIST ANTIBODIES
#1274ANTI-CORTICOTROPIN-RELEASING HORMONE ANTIBODIES AND USE IN CONGENITAL ADRENAL HYPERPLASIA
#1275IL-21 POLYPEPTIDES AND TARGETED CONSTRUCTS
#1276ANTI-INTERLEUKIN-11 ANTIBODY AND USE THEREOF
#1277ANTI-PD-1/VEGFA BIFUNCTIONAL ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
#1278Anti-ED-A Antibodies for the Treatment of Pulmonary Hypertension
#1279ANTIBODIES TO NECROTIC ENTERITIS B-LIKE TOXIN
#1280NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE
#1281Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies
#1282USES FOR ATTENUATED IL-2 IMMUNOCONJUGATES
#1283High Concentration Bispecific Antibody Formulations
#1284COMBINATION OF MULTISPECIFIC MOLECULE AND IMMUNE CHECKPOINT INHIBITOR
#1285IMMUNOTHERAPEUTIC CONSTRUCTS AND METHODS OF THEIR USE
#1286Therapeutic Compositions for the Treatment of Dry Eye Disease
#1287GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY
#1288METHOD FOR REDUCTION OF IMMUNE CHECKPOINT THERAPY RELATED ADVERSE EVENTS
#1289CXCR4/CXCR7 Blockade and Treatment of Human Papilloma Virus-Associated Disease
#1290METHODS OF BLOOD SCREENING
#1291COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMA BY INHIBITION OF THE TFPI2-CD51-STAT6 SIGNALING AXIS
#1292Method of treatment
#1293GLYCOFORM SPECIFIC NANOBODIES AND METHODS OF USE
#1294ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF
#1295IN UTERO TREATMENT OF A FETUS HAVING GENETIC DISEASE/NEUROMUSCULAR DISEASE
#1296COMPOSITIONS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND METHODS FOR MAKING AND USING THE SAME
#1297USE OF PROTOCADHERINS IN METHODS OF DIAGNOSING AND TREATING CANCER
#1298ANTI-CD137 ANTIBODIES AND METHODS OF MAKING AND USING THE SAME
#1299BINDING PROTEINS AND METHODS OF USE THEREOF
#1300Method of Treating an Eosinophil-Associated Disease
#1301COMPOSITIONS TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS FOR MAKING AND USING THE SAME
#1302COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND CMET
#1303COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2b ANTIBODIES
#1304GPRC5D ANTIBODIES WITH ENHANCED EFFECTOR FUNCTION AND USES THEREOF
#1305TGF-ß ANTIBODIES
#1306ANTIBODY BINDING TO CLOSTRIDIUM DIFFICILE
#1307ANTIBODY COMPOSITIONS FOR DISRUPTING BIOFILMS
#1308CORONAVIRUS ANTIBODIES AND USES THEREOF
#1309HMPV ANTIBODIES AND THEIR USE
#1310MAGNETIC RESONANCE IMAGE PROCESSING APPARATUS AND METHOD TO WHICH IMPROVEMENT IN SLICE RESOLUTION IS APPLIED
#1311MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#1312METHODS OF TREATING BILIARY TRACT CANCER USING ANTI-PD-L1 ANTIBODY IN COMBINATION WITH CHEMOTHERAPY
#1313METHODS FOR TREATING CANCER
#1314COMBINATION THERAPY COMPRISING DGK INHIBITORS and PD-1/PD-L1 INHIBITORS
#1315ORGANIC COMPOUNDS
#1316METHODS OF TREATING CANCER AND OTHER CONDITIONS WITH A MU OPIOID RECEPTOR ANTAGONIST
#1317METHODS OF TREATING INFLAMMATORY AND/OR ALLERGIC DISORDERS WITH NORKETOTIFEN
#1318DUAL INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY
#1319THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER
#1320Cancer Neoepitopes
#1321METHODS OF ADMINISTERING FVIII MIMETIC BISPECIFIC ANTIBODIES ONCE MONTHLY
#1322PHARMACEUTICAL COMPOSITION COMPRISING ANTI-FXI/FXIA ANTIBODY AND USE THEREOF
#1323Antibodies and antibody fragments and analogues specific for chondroitin sulfate
#1324ANTI-CD26 ANTIBODIES AND USE THEREOF
#1325NOVEL BISPECIFIC ANTIGEN BINDING MOLECULES CAPABLE OF SPECIFIC BINDING TO CD40 AND TO FAP
#1326ANTI GLUCOCORTICOID-INDUCED TNFR-RELATED (GITR) PROTEIN ANTIBODIES AND USES THEREOF
#1327Antibodies That Specifically Bind to TL1A and Methods of Treating Skin Disease
#1328METHODS AND COMPOSITIONS FOR INCREASING GALACTOSIDASE BETA-1 ACTIVITY IN THE CNS
#1329COMPOSITIONS AND METHODS RELATED TO IL27 RECEPTOR BINDING
#1330HETEROMERIC AGONISTIC ANTIBODIES TO IL-18 RECEPTOR
#1331ANTI-FLT3 ANTIBODIES AND COMPOSITIONS
#1332TREATMENT WITH AN ANTIBODY THAT BINDS EGFR AND CMET
#1333BISPECIFIC DENDRITIC CELL ENGAGER AND USES THEREOF
#1334Integrin Alpha10 Antibody
#1335DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES
#1336ANTI PD-L2 ANTIBODY
#1337ANTI-TREM1 ANTIBODIES AND RELATED METHODS
#1338NK/MONOCYTE ENGAGERS
#1339MULTI-SPECIFIC BINDING PROTEINS AND METHODS OF USE THEREOF
#1340ANTI-TIGIT ANTIBODIES AND USES OF THE SAME
#1341ANTI-CD160 TRANSMEMBRANE ISOFORM ANTIBODIES
#1342COMBINATION THERAPY FOR TREATMENT OF DISEASE
#1343MATERIALS AND METHODS FOR TREATING STRESS-RELATED DISORDERS AND CANCER
#1344LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF
#1345Anti-Abeta Antibodies
#1346COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF IRON-RELATED DISORDERS
#1347COMPOSITIONS OF ANTI-C5 MONOCLONAL ANTIBODY
#1348A-FABP ANTIBODIES FOR DIAGNOSIS AND TREATMENT OF OBESITY-ASSOCIATED DISEASES
#1349ANGIOPOIETIN-LIKE 4 ANTIBODIES AND METHODS OF USE
#1350NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE
#1351RSV-SPECIFIC ANTIBODIES AND FUNCTIONAL PARTS THEREOF
#1352SARS-COV-2 NEUTRALIZING SYNTHETIC PROTEINS
#1353SPIKE FURIN CLEAVAGE IS A SARS-COV-2 TARGETING STRATEGY TO BREAK THE CHAIN OF INFECTION CYCLE
#1354NON-INTEGRATING VIRAL DELIVERY SYSTEM AND METHODS RELATED THERETO
#1355FUNCTIONALIZED NANOPARTICLES FOR THE CONTAINMENT AND CLEARANCE OF PATHOGENS
#1356MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF
#1357MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#1358ROR1-TARGETED BINDING MOLECULE AND USE THEREOF
#1359RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS
#1360CANCER VACCINE COMPRISING EPITOPE OF C-MET AND EPITOPE OF HIF1ALPHA, AND USE THEREOF
#1361USE OF IMMUNOSUPPRESSION TO ENABLE ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS
#1362COMBINATION THERAPY OF PI3K INHIBITOR AND PD-1 INHIBITOR
#1363METHODS RELATED TO ADMINISTERING IMMUNOSUPPRESSANTS AND THERAPEUTIC MACROMOLECULES AT A REDUCED PHARMACODYNAMICALLY EFFECTIVE DOSE
#1364COMBINATION TREATMENT FOR CANCER
#1365AUTOMATED HEART VALVE MANUFACTURING
#1366METHODS AND COMPOSITIONS FOR CAR T CELL THERAPY
#1367DISPLACERS OF IGE-FCERI
#1368ANTI-CD38 ANTIBODIES
#1369HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION
#1370THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISORDER
#1371MULTISPECIFIC ANTIBODIES FOR TREATING CD47-ASSOCIATED DISEASES
#1372HUMANIZED COMPLEMENT 5A RECEPTOR 1 ANTIBODIES AND METHODS OF USE THEREOF
#1373METHODS OF TREATING COMPLEMENT-MEDIATED DISEASE
#1374Bispecific Constructs for Target and Complement Engagement
#1375METHODS FOR TREATING PROGRESSIVE MULTIPLE SCLEROSIS
#1376ANTI-CCR8 ANTIBODIES AND USES THEREOF
#1377IL27RAlpha BINDING MOLECULES AND METHODS OF USE
#1378DUPILUMAB FOR TREATMENT OF COVID-19
#1379NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
#1380TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
#1381METHOD OF TREATING DISEASE USING ANTI-CD47 X ANTI-MESOTHELIN ANTIBODIES AS A SOLE AGENT AND IN COMBINATION WITH ANTI-PD-1 ANTIBODIES
#1382COMPOSITIONS AND METHODS FOR DEPLETION OF DISEASED HEMATOPOIETIC STEM CELLS
#1383KIR3DL3 INHIBITORS AND IMMUNE CELL ACTIVATING AGENTS
#1384Method of Treating Inflammatory Bowel Disease with a Combination Therapy of Antibodies to IL-23 and TNF Alpha
#1385Combination of Broadly Neutralizing HIV Antibodies and Viral Inducers
#1386RADIOLABELING OF POLYPEPTIDES
#1387ANTI-ROR2 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOF
#1388ANTI-EGFR ANTIBODY-DRUG CONJUGATES
#1389MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#1390STABLE, AQUEOUS FORMULATIONS OF ANTIBODIES THAT BIND IL5 RECEPTOR
#1391MDR E. COLI IMMUNOGEN
#1392COMBINATIONS OF STAT-INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT AND/OR MANAGEMENT OF CANCER
#1393Carrier-Binding Agent Compositions and Methods of Making and Using the Same
#1394BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#1395METHODS AND COMPOSITIONS FOR TREATING MMP-9 MEDIATED DISORDERS
#1396CAMELID ANTIBODIES AGAINST ACTIVATED PROTEIN C AND USES THEREOF
#1397ENPP3 AND CD3 BINDING AGENTS AND METHODS OF USE THEREOF
#1398ANTI-PROTHROMBIN ANTIBODIES TARGETING THE OPEN FORM OF PROTHROMBIN
#1399ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF
#1400CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
#1401MONOCLONAL ANTIBODY AGAINST TROP2 AND USE THEREOF
#1402pH-DEPENDENT ANTI-SULFATED GLYCOSAMINOGLYCAN ANTIBODY AND ANTIBODY-DRUG CONJUGATE
#1403CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER
#1404MONOVALENT BLOOD BRAIN BARRIER SHUTTLE MODULES
#1405Combination Treatment for Cancer
#1406HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLS
#1407ANTIBODY FORMULATION
#1408NOVEL ANTIBODIES AND ANTIBODY CONJUGATES FOR THE TREATMENT OF METABOLIC DISORDERS
#1409Human Antigen Binding Proteins That Bind Beta-Klotho, FGF Receptors and Complexes Thereof
#1410ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#1411PHARMACEUTICAL COMPOSITION CONTAINING ANTI-INTEGRIN ALPHA11 ANTIBODY FOR TREATMENT OR PREVENTION OF AGING-RELATED DISEASES
#1412NOVEL MONOCLONAL ANTIBODIES TO CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4 (CTLA-4)
#1413COMBINATION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT TUMORS
#1414METHODS FOR MODULATING INTESTINE CELLS OR TISSUE FUNCTION
#1415ANTI-CAR COMPOSITIONS AND METHODS
#1416Pharmaceutical Composition For Treating Or Preventing At Least One Disease Selected From Group Consisting Of Inflammatory Bowel Disease And Intestinal Tumor
#1417NOVEL Nav1.7 MONOCLONAL ANTIBODY
#1418IL-23 Specific Antibodies for the Treatment of Systemic Sclerosis
#1419ANTI-FGF23 ANTIBODY OR ANTIBODY FRAGMENT THEREOF
#1420POLYPEPTIDES THAT BIND COMPLEMENT COMPONENT C5 OR SERUM ALBUMIN AND FUSION PROTEINS THEREOF
#1421BIOMARKERS FOR ALZHEIMER'S DISEASE TREATMENT
#1422METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
#1423METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
#1424METHODS OF ADMINISTERING SECUKINUMAB
#1425COMPOSITIONS AND METHODS FOR TREATMENT OF PSORIASIS
#1426THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE DISEASE
#1427PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS
#1428CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS
#1429ANTI-PCSK9 ANTIBODIES
#1430METHODS OF TREATING BLOOD DISORDERS WITH VWF-TARGETED MONOSPECIFIC ANTIBODIES
#1431METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#1432ANTI-STEAP1 ANTIGEN-BINDING PROTEIN
#1433ANTI-GPC3 AND ANTI-CD137 MULTISPECIFIC ANTIBODIES AND METHODS OF USE
#1434APPLICATION OF CD45 AS BIOMARKER IN SCREENING EFFECTIVENESS AND PRECISION OF CD26 ANTIBODY OR DERIVATIVE THEREOF IN TREATING TUMORS
#1435ANTI-CD3 AND ANTI-CD20 BISPECIFIC ANTIBODY AND USE THEREOF
#1436USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT
#1437PD-L1 and OX40 Binding Proteins for Cancer Regulation
#1438ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY
#1439ANTI-NGF ANTIBODIES AND METHODS OF TREATING PAIN THEREOF
#1440ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOF
#1441ACTIVIN SIGNALING ACTIVITY
#1442Anti-cMET Antibodies and Methods of Use
#1443ANTI-ALK1 ANTIBODIES AND METHODS OF USING THE SAME
#1444FUSION PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF
#1445ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1
#1446DOSING REGIMEN FOR BCMAx-CD3 ANTIBODIES CONSTRUCTS
#1447HUMAN ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF
#1448TARGETING CD47 WITH Fc-ENHANCED ACTIVITY
#1449TREATMENT OF CARDIOVASCULAR DISEASES USING ANTI-HUMAN GPVI ANTIBODIES
#1450CEACAM5 ADC-ANTI-PD1/PD-L1 COMBINATION THERAPY
#1451ANTI-SLC34A2 MONOCLONAL ANTIBODIES AND USES THEREOF
#1452CANCER TREATMENT TARGETING DLL3
#1453MONOCLONAL ANTI-IL-1RACP ANTIBODIES
#1454ANTI-IL-27 ANTIBODIES AND USES THEREOF
#1455COMBINATION TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN PATIENTS WITH RAS PATHWAY MUTATIONS
#1456ANTI-TNF-ALPHA ANTIBODIES AND COMPOSITIONS
#1457ANTIGEN BINDING PROTEINS CAPABLE OF BINDING THYMIC STROMAL LYMPHOPOIETIN
#1458ANTI-HUMAN CXCL1 ANTIBODY
#1459METHOD FOR PREVENTING OR TREATING SKIN AGING OR INFLAMMATION OR INCREASING A CONTENT OF COLLAGEN
#1460METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING FIBROSIS
#1461PREVENTION AND TREATMENT OF HEADACHES
#1462ANTIBODY-BASED THERAPY OF TRANSTHYRETIN (TTR) AMYLOIDOSIS AND HUMAN-DERIVED ANTIBODIES THEREFOR
#1463METHODS FOR TREATMENT OF REFRACTORY GENERALIZED MYASTHENIA GRAVIS
#1464HIGH CONCENTRATION ANTI-C5 ANTIBODY FORMULATIONS
#1465DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF MYASTHENIA GRAVIS
#1466D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF
#1467MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#1468CD70 COMBINATION THERAPY
#1469Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders
#1470CANCER-CELL PROLIFERATION INHIBITOR AND CANCER-CELL-PROLIFERATION INHIBITION ENHANCER
#1471USE OF TUMOR MUTATIONAL BURDEN AS A PREDICTIVE BIOMARKER FOR IMMUNE CHECKPOINT INHIBITOR VERSUS CHEMOTHERAPY EFFECTIVENESS IN CANCER TREATMENT
#1472METHODS COMPRISING ONCOLYTIC VIRUSES EXPRESSING CD19T AND BISPECIFIC T CELL ENGAGERS
#1473HUMANIZED ANTIBODIES AGAINST IRHOM2
#1474TISSUE FACTOR PATHWAY INHIBITOR ANTIBODIES AND USES THEREOF
#1475ANTI-IMMUNOGLOBULIN DEGRADING ENZYME-DIGESTED FC VARIANT
#1476POLYPEPTIDE ENGINEERING, LIBRARIES, AND ENGINEERED CD98 HEAVY CHAIN AND TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
#1477HUMAN IGG1 FC REGION VARIANTS AND USES THEREOF
#1478IMMUNOSUPPRESIVE AGENT
#1479ANTI-PDL1 ANTIBODY FORMULATIONS
#1480B7-H3 TARGETING FUSION PROTEINS AND METHODS OF USE THEREOF
#1481TREATMENT OF RENAL CELL CARCINOMA
#1482CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USE
#1483ANTIBODIES TARGETING THE B-CELL RECEPTOR OF CHRONIC LYMPHOCYTIC LEUKEMIA AND USES THEREOF
#1484AUTOANTIBODIES AGAINST NaV1.5 CHANNEL AS BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME AND RELATED THERAPEUTIC METHODS
#1485ANTI-IL-17A ANTIBODIES AND THEIR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS
#1486EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE
#1487BISPECIFIC ANTIBODY AND APPLICATION THEREOF
#1488SUBCUTANEOUS DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
#1489ANTIBODY-BASED THERAPY OF TRANSTHYRETIN (TTR) AMYLOIDOSIS AND HUMAN-DERIVED ANTIBODIES THEREFOR
#1490ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
#1491ANTI-APOE ANTIBODIES
#1492METHODS FOR TREATING COMPLEMENT-MEDIATED DISEASES AND DISORDERS
#1493Humanized Anti-TDP-43 Binding Molecules and Uses Thereof
#1494HERV-K ANTIBODY, CELL, VACCINE, AND DRUG THERAPEUTICS
#1495HUMAN MONOCLONAL ANTIBODIES THAT BROADLY TARGET CORONAVIRUSES
#1496Therapeutic Biologic For Treatment Of Glioblastoma
#1497FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES
#1498POLYPEPTIDES FOR COMPLEMENT INHIBITION
#1499DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AND ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
#1500COMBINATION THERAPY COMPRISING ANTI-CCR9 ANTIBODY AND VINCRISTINE FOR CANCER